Alkermes plc (ALKS)
Alkermes plc (ALKS) is a healthcare company (drug manufacturers - specialty & generic) based in Ireland. The share price is $45.38, down 2.47% on the day, which values the company at $7.63B. Price as of 17 Nov 2026, 17:23 UTC, from Yahoo Finance.
Key facts
- Share price
- $45.38−2.47% today
- Market value
- $7.63B
- Forward P/E
- 33.5×
- Funk Score
- 70/100
- Against its own history
- About its usual priceusual price $42.25
- 200-week average
- $31.2445% above
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Alkermes plc in more detail
ALKS trades at 33.5× next year's expected earnings, 4.3× sales. Measured against its own history, the price is 7% above what its usual multiples would imply ($42.25) — about its usual price. It sits 45% above its 200-week average of $31.24.
Over the last five fiscal years Alkermes plc has compounded revenue 7.3% a year, free cash flow 63.9% a year. Its Funk Score is 70 out of 100 (financial strength 9.6, profitability 7.0, growth 6.0, value 5.3, each out of 10).
In its favour: Altman Z in the safe zone; Strong Piotroski score.
4 of the superinvestors tracked here hold ALKS, including Julian and Felix Baker (2.6% of the portfolio), Brandon Haley (0.4% of the portfolio), Jim Simons (1938–2024) (0.4% of the portfolio).
Superinvestors holding ALKS
4 of the investors tracked here report a position in their latest 13F filing.
- Julian and Felix Baker Baker Bros. Advisors2.63% of portfolio · $524.6M · Q2 2026
- Brandon Haley Holocene Advisors0.43% of portfolio · $188.7M · added · Q2 2026
- Jim Simons (1938–2024) Renaissance Technologies0.36% of portfolio · $263.1M · added · Q3 2026
- Doug Silverman Senator Investment Group0.30% of portfolio · $8M · trimmed · Q3 2026
Health Care companies of similar size
- HealthEquityHQY
- Corcept TherapeuticsCORT
- Rhythm PharmaceuticalsRYTM
- PACS GroupPACS
- Kiniksa Pharmaceuticals InternationalKNSA
- ImmunityBioIBRX
- CytokineticsCYTK
- ABIVAXABVX
- Bausch + LombBLCO
- Amneal PharmaceuticalsAMRX
- Caris Life SciencesCAI
- ImmunovantIMVT
Side by side:ALKS vs PACS (Alkermes plc vs PACS Group)ALKS vs KNSA (Alkermes plc vs Kiniksa Pharmaceuticals International)ALKS vs IBRX (Alkermes plc vs ImmunityBio)ALKS vs CYTK (Alkermes plc vs Cytokinetics)ALKS vs ABVX (Alkermes plc vs ABIVAX)
All health care companies by market valueLargest companies in IrelandAll stocks A–Z
Alkermes plc (ALKS): questions and answers
What is ALKS's PEG ratio?
Alkermes plc's PEG ratio is 1.96 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.
What is Alkermes plc's market cap?
Alkermes plc is valued at $7.63B at a share price of $45.38.
Is ALKS overvalued or undervalued?
Against its own history, ALKS is about its usual price: the price is 7% above the $42.25 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is ALKS above its 200-week moving average?
Yes. ALKS is 45.3% above its 200-week average of $31.24. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is Alkermes plc growing?
Over the last five fiscal years Alkermes plc's revenue grew 7.3% a year; over ten years revenue grew 8.9% a year.
Does ALKS pay a dividend?
Alkermes plc does not currently pay a regular dividend.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Alkermes plc (ALKS) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/ALKS
Underlying data: Yahoo Finance; company filings with the SEC.